Chung AH, Leisner TM, Dardis GJ, Bivins MM, Keller AL, Parise LV. CIB1 depletion with docetaxel or TRAIL enhances triple-negative breast cancer cell death. Cancer Cell Int. 2019 Feb 4;19(26). doi: 10.1186/s12935-019-0740-2
Magrey M, Wolin DL, Mordin MM, McLeod LD, Davenport EK, Hur P. US patient satisfaction with Secukinumab treatment among patients with both psoriatic arthritis and psoriasis: data from a web-based survey. Poster presented at the 2018 Winter Clinical Dermatology Conference; January 2018. Hawaii. [abstract] Skin: the journal of cutaneous medicine. 2018 Feb 23; 2(2018). doi: 10.25251/skin.2.supp.25
Glaser DA, Hebert AA, Fehnel S, DiBenedetti D, Nelson L, Drew J, Pariser DM. Confirmatory psychometric evaluation of the axillary sweating daily diary: a vaildated patient-reported outcome measure to assess axillary hyperhidrosis sweating severity. Poster presented at the 36th Fall Clinical Dermatology Conference; October 2017. Las Vegas, NV. [abstract] Skin: the journal of cutaneous medicine. 2017; 1(Suppl 93):s94. doi: 10.25251/skin.1.supp.93.
Ward MA, Fang G, Richards KL, Walko CM, Earnshaw SR, Happe LE, Blalock S. Treatment interruption and regimen change in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. JHEOR. 2015 Apr;2(2):181-91.
Davis KL, Gutierrez B, Zyczynski T, Kaye JA. Real-world treatment patterns in men with castration-resistant prostate cancer receiving docetaxel. JHEOR. 2015 Jan 6;2(2):119-30. doi: 10.36469/9894